title: A population-based study of gefitinib in patients with non-small cell lung cancer.
abstract: Survival data for non-small cell lung cancer is typically reported from clinical trials that include patients fit enough to meet treatment criteria. The denominator of all patients from which the gefitinib-treated population is derived has rarely been reported and the impact of gefitinib on population-based outcomes is difficult to measure. We have retrospectively reviewed data of 626 patients who received gefitinib in Ibaraki Prefecture (with a population of 3 million) in Japan from July 2002 until September 2007. Overall response rate was found to 30.8%, and the median survival time was 8.0 months (95% confidence interval: 7.0-9.0 months). Female gender, good PS, and adenocarcinoma were significantly associated with prolonged survival. Adverse events were generally mild and were mostly skin reactions and diarrhea. Our population-based study has generated similar results to those previously reported in published clinical trials, which had restrictive criteria for eligible patients.
authors.affiliation: Ibaraki Higashi Hospital, Ibaraki, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Hayashibara
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Satoh
authors.forename: Yoko
authors.initials: Y
authors.lastname: Shinohara
authors.forename: Masaharu
authors.initials: M
authors.lastname: Inagaki
authors.forename: Takayuki
authors.initials: T
authors.lastname: Kaburagi
authors.forename: Toshio
authors.initials: T
authors.lastname: Hashimoto
authors.forename: Koichi
authors.initials: K
authors.lastname: Kurishima
authors.forename: Hiroichi
authors.initials: H
authors.lastname: Ishikawa
authors.forename: Hideo
authors.initials: H
authors.lastname: Ichimura
authors.forename: Takeshi
authors.initials: T
authors.lastname: Nawa
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Funayama
authors.forename: Takeshi
authors.initials: T
authors.lastname: Matsumura
authors.forename: Katsunori
authors.initials: K
authors.lastname: Kagohashi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Endo
authors.forename: Kinya
authors.initials: K
authors.lastname: Furukawa
authors.forename: Koji
authors.initials: K
authors.lastname: Kishi
authors.forename: Masaaki
authors.initials: M
authors.lastname: Sumi
authors.forename: Koichi
authors.initials: K
authors.lastname: Kamiyama
authors.forename: Shigemi
authors.initials: S
authors.lastname: Ishikawa
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018287:Carcinoma, Large Cell / Q000188:drug therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D003710:Demography; D005260:Female; D000077156:Gefitinib; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D012907:Smoking / Q000453:epidemiology
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib